All Eyes On Early Post-Shire Performance Ahead Of Takeda Q4
Executive Summary
The first real indications of how Shire is contributing to Takeda will come when the Japanese firm issues its annual results next week, and investors will also be keeping a keen eye on the critical first forward guidance for the combined company.
You may also be interested in...
Takeda's Entyvio Beats Humira In Head-To-Head Ulcerative Colitis Trial
Takeda’s gut-selective biologic vedolizumab pushes ahead of other biologics in the race to make its mark in ulcerative colitis, a therapeutic sector targeted by numerous new investigational therapies.
Takeda Says Last Pre-Shire Quarter ‘Robust’, But Quiet On Divestments
Takeda saw continued growth for mainstay drugs in what it described as a ‘robust’ last quarter of reporting before the inclusion of Shire, with global blockbuster Entyvio leading the way, but gave away little new on widely anticipated post-deal divestments.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.